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A BST R A C T 
Parkinson’s  disease  (PD)  is  the  second  most  prevalent  neurodegenerative  disease 
among aging individuals, affecting greatly the quality of their life. However, the 
pathogenesis of Parkinson's disease is still incompletely understood to date. 
Increasing experimental evidence suggests that cell cycle reentry of postmitotic 
neurons precedes many instances of neuronal death. Since cell cycle dysfunction is 
not restricted to neurons, we investigated this issue in peripheral cells from patients 
suffering from sporadic PD and age-matched control individuals. Here, we describe 
increased cell cycle activity in immortalized lymphocytes from PD patients, that is 
associated to enhanced activity of the cyclin D3/CDK6 complex, resulting in higher 
phosphorylation of the pRb family protein and thus, in a G1/S regulatory failure. 
Decreased degradation of cyclin D3, together with increased p21 degradation, as well 
as elevated levels of CDK6 mRNA and protein were found in PD lymphoblasts. 
Inhibitors of cyclin D3/CDK6 activity like sodium butyrate, PD-332991, and 
rapamycin were able to restore the response of PD cells to serum stimulation. We 
conclude that lymphoblasts from PD patients are a suitable model to investigate cell 
biochemical aspects of this disease. It is suggested that cyclin D3/CDK6-associated 





1. IN T R O DU C T I O N 
 
Parkinson’s  disease  (PD)  is  the  second  most  common  neurodegenerative  disorder, 
affecting to 1.8% of population over 65 years old [1]. PD is associated with selective 
loss of dopaminergic neurons in the nigrostriatal pathway of the brain, and 
pathologically it is characterized by the presence of Lewy bodies, whose primary 
structural component is alpha-synuclein. Nevertheless, it has become increasingly 
evident that the distribution of Lewy bodies is much greater than formerly 
appreciated, extending to peripheral nervous systems, most notably, the enteric 
nervous system [2], where it occurs very early in the disease process [3]. Clinical 
manifestations include motor abnormalities (tremor, rigidity, slowness, balance 
problems), autonomic disturbances, and nonmotor symptoms (depression and 
cognitive impairment). The cause of PD is still unknown. Only in a minority of cases 
is PD determined by major gene mutations, while approximately 90% of cases are 
considered sporadic. Nongenetic factors, probably interacting with susceptibility 
genes are thought to play the most important role in sporadic PD. 
The pathogenic mechanisms underlying the selective dopaminergic cell loss in PD are 
not well understood. Mitochondrial dysfunction, oxidative stress, and protein 
mishandling seem to play a central role in PD pathogenesis [4]. Moreover, a wealth of 
data accumulated over the past years, indicate that in PD, as well as in other 
neurodegenerative diseases, there is a loss of cell cycle control, leading eventually to 
neuronal death [5-7]. Gene and protein signature in sporadic PD have revealed 
significant alterations in the expression of genes linked to cell cycle regulation [8]. 
On the other hand, increasing evidence indicates that peripheral tissue shares 
significant protein/gene expression similarities to inaccessible central nervous system 
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(CNS) tissues [9-11] and thus may offer valuable surrogate markers for 
neuropsychiatric disorders. Peripheral blood mononuclear cells (PBMCs) from PD 
patients appear to reflect molecular events related to PD pathogenesis, i.e changes in 
dopamine expression, as well as in the levels of proteins involved in dopamine 
metabolism, have been described in peripheral cells [12]. In addition, mitochondrial 
dysfunction [13], and impaired ubiquitin-proteasome system [14] have been reported.   
The present work was undertaken to gain insight into the possible role of cell cycle 
deregulation in PD. For this purpose, we have used lymphoblastoid cell lines obtained 
by infecting PBMCs with the Epstein Barr virus (EBV). Although the viral infection 
and transformation could affect the cell-cycle machinery, we have previously 
demonstrated that the EBV-immortalized lymphocytes retain the cellular response of 
either PBMCs or CD-19 B-lymphocytes upon stimulation with mitogens, finding 
similar changes in cell proliferation and survival, as well as in the content of certain 
cell-cycle regulatory and signaling proteins [15,16]. Therefore, easily accessible 
blood cells from sporadic PD patients appears be a useful model to study cell cycle-
related events in PD pathology, obviating the difficulty of obtaining repeated blood 
samples from such a vulnerable population as patients suffering from PD. 
We report here a serum-mediated enhancement of proliferation of lymphoblasts from 
sporadic PD patients associated with a cyclin D3/CDK6-dependent 
hyperphosphorylation of pRb. Upregulation of CDK6 expression, together with 
alterations in the rate of degradation of cyclin D3 and p21, resulting in higher or 
lower cellular content respectively, appeared to have a causative role in this 
phenomenon since cell treatment with specific cyclin D3/CDK6-associated kinase 
activity inhibitors prevented the increased rates of phosphorylation of pRb and cell 
proliferation observed in these cell lines.  
 5 
2. M A T E RI A LS A ND M E T H O DS 
2.1. Materials 
All components for cell culture were obtained from Invitrogen (Carlsbad, CA). The 
kinase inhibitor PD-332991 was kindly provided by Pfizer. The inhibitor of histone 
deacetylases sodium butyrate (NaB), cycloheximide (CHX), and rapamycin were 
obtained from Sigma-Aldrich. PVDF (polyvinylidene difluoride) Immobilon-P 
membranes for Western blots were purchased from Millipore. Rabbit anti-human 
antibodies, such as pRb (sc-50), p107 (sc-318), p130 (sc-317), Cyc E (sc-198), CDK6 
(sc-177), CDK4 (sc-260), CDK2 (sc-748) and p16 (sc-468), and mouse anti-human 
antibodies -tubulin (sc-23948) and p18 (sc-9965) were from Santa Cruz 
Biotechnologies. Mouse monoclonal antibody anti-human p27 was from BD 
Transduction Laboratories. Mouse anti-human Cyc D3 and rabbit anti-human 
antibodies such as Cyc D2 and p21 were obtained from Cell Signaling. Rabbit anti-
human TDP-43 antibody was from Proteintech Group. Rabbit anti-human -actin 
antibody was from Sigma. Mouse anti-human Lamin B was from Calbiochem. The 
enhanced chemiluminiscence (ECL) system was from Amersham. All other reagents 
were of molecular grade.  
2.2. Cell lines 
A total of 20 patients were diagnosed in the department of Neurology of the 
University Hospital 12 de Octubre (Madrid, Spain) of sporadic Parkinson disease 
following Diagnostic Criteria published elsewhere [17]. All patients were undergoing 
treatment with levodopa. The average age of the patients group was 6910 and the 
age range 49-83 years old. A group of 21 age-matched individuals was used as control 
(average age 6810, age range 48-83). The control group was formed of family 
members or caregivers of the PD patients, and showed a completely normal cognitive 
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and functional level. In all cases peripheral blood samples were obtained after written 
informed consent of the donors. PBMCs were isolated on Lymphoprep™ density-
gradient centrifugation according to the instructions of the manufacturer (Axix-
Shield). Cells were washed twice with phosphate buffered saline (PBS), counted, and 
resuspended at the desired concentration.  
Establishment of lymphoblastoid cell lines was performed in our laboratory as 
previously described [18] by infecting PBMCs with the Epstein Barr Virus (EBV). 
Cells were grown in suspension in T flasks in an upright position, in approximately 10 
mL RPMI 1640 (Gibco, BRL) medium that contained 2 mM L-glutamine, 100 µg/mL 
penicillin/streptomycin and, unless otherwise stated, 10% (v/v) fetal bovine serum 
(FBS) and maintained in a humidified 5% CO2 incubator at 37 ºC. Fluid was routinely 
changed every 3 days by removing the medium above the settled cells and replacing it 
with an equal volume of fresh medium. 
2.3. Determination of cell proliferation 
EBV-immortalized lymphocytes were seeded at an initial cell concentration of 1 x 106 
x mL-1, and cells were enumerated everyday thereafter. The cell suspension was 
mixed with a 0.4% (w/v) Trypan Blue solution (Sigma), and the number of live cells 
was determined using a Neubauer  chamber,  and,  for  some  experiments,  a  TC10™ 
Automated Cell Counter from Bio-Rad Laboratories, S.A. Cells failing to exclude the 
dye were considered nonviable. 
In addition, cell proliferation was assessed in some experiments by the 5-bromo-2’-
deoxyuridine (BrdU) incorporation method, using an enzyme-linked immunoassay kit 
procured from Roche. Cells (100,000 cells/well) were seeded in 96-well microtiter 
plates. Four hours prior to the end of the interval of measurement, BrdU (10 μM) was 
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added. The cells were fixed with precooled 70% ethanol for 30 min at -20 ºC and 
incubated with nucleases following manufacturer’s recommendations. Cells were then 
treated for 30 min at 37 ºC with peroxidase-conjugated anti-BrdU antibody. The 
excess of antibody was removed by washing the cells three times, followed by the 
addition of substrate solution. Absorbance was measured at 405 nm with a reference 
wavelength of 490 nm. 
2.4. Preparation of whole-cell extracts and subcellular fractionation 
To prepare whole-cell extracts, cells were harvested, washed in PBS and then lysed in 
ice-cold buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF, 1% Nonidet P-40), 
containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate 
and protease inhibitor Complete Mini Mixture (Roche).  
To separate the cytosolic and nuclear fractions, cells were harvested, washed in PBS 
and then lysed in ice-cold hypotonic buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 
mM ethylendiaminetetraacetic acid (EDTA), 0.1 mM ethylene glycol tetraacetic acid 
(EGTA), 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 1 mM PMSF 
and protease inhibitor mixture). After extraction on ice for 15 minutes, 0.5% Nonidet 
P-40 was added and the lysed cells were centrifuged at 4000 rpm for 10 minutes. 
Supernatants containing cytosolic proteins were separated, and nuclei were washed 
twice with the hypotonic buffer, and then lysed in hypertonic buffer (20 mM HEPES, 
pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM 
sodium pyrophosphate, 1 mM PMSF and protease inhibitor mixture). After extraction 
on ice for 30 minutes, the samples were centrifuged at 15000 rpm for 15 minutes at 4 
ºC.  Antibodies  to  α-tubulin and to lamin B were used to assess the purity of the 
fractions. 
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The protein content of the extracts was determined by the Pierce BCA Protein Assay 
kit (Thermo Scientific). 
2.5. Western Blot Analyses 
50-100 g of protein from cell extracts were fractionated on a SDS polyacrylamide 
gel, and transferred to a PVDF membrane which was then blocked with 1-5% bovine 
serum albumin (BSA) or 5% nonfat milk, and incubated overnight at 4 ºC, with 
primary antibodies at the following dilutions: 1:500 anti-pRb, 1:500 anti-p130, 1:500 
anti-p107, 1:500 anti-CycE, 1:200 anti-CycD2, 1:500 anti-CycD3, 1:500 anti-CDK2, 
1:500 anti-CDK4, 1:1000 anti-CDK6, 1:1000 anti-p21, 1:500 anti-p27, 1:500 anti-
p16, 1:200 anti-p18, 1:500 anti-TDP43, 1:5000 anti--actin, 1:1000 anti--tubulin, 
1:1000 anti-Lamin B. Signals from the primary antibodies were amplified using 
species-specific antisera conjugated with horseradish peroxidase (Bio-Rad) and 
detected with a chemiluminiscent substrate detection system ECL (Amersham). The 
specificity of the antibodies used in this work was checked by omitting the primary 
antibodies in the incubation medium. Protein band densities were quantified using 
Image J software (NIH, Bethesda, Maryland, USA) after scanning the images with a 
GS-800 densitometer from Bio-Rad.  
2.6. Quantitative Real-T ime PC R 
Total RNA was extracted from cell cultures using Trizol™ reagent (Invitrogen). RNA 
yields were quantified spectrophotometrically and RNA quality was checked by the 
A260/A280 ratio and on a 1.2% agarose gel to observe the integrity of 18S and 28S 
rRNA. RNA was then treated with DNase I Amplification Grade (Invitrogen). One 
microgram was reverse transcribed with the Superscript III Reverse Transcriptase kit 
(Invitrogen). Quantitative real-time PCR was performed in triplicates using 
TaqMan™  Universal  PCR  MasterMix  No  Amperase  UNG  (Applied Biosystems) 
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reagent  according  to  the manufacturer’s  protocol.  Primers  were  designed  using  the 
Universal Probe Library for Human (Roche Applied Science) and used at a final 
concentration of 20 M. The sequences of the forward and reverse primers used are 
the  following:  for  CDK6  5’-tgatcaactaggaaaaatcttggac-3’  and  5’-
ggcaacatctctaggccagt-3’;  for  cyc  D3  5’-ctttcctaaggctgcaaggtt-3’  and  5’-
caagaagccaaagccagttt-3’  (these  primers  recognized  the  four  transcript  variants  of 
CCND3 gene); for p21 5’-cgaagtcagttccttgtggag-3’ and 5’-catgggttctgacggacat-3’; for 
-actin 5’-ccaaccgcgagaagatga-3’ and 5’-ccagaggcgtacagggatag-3’. 
Real time quantitative PCR was performed in the Bio-Rad iQ5 system using a thermal 
profile of an initial 5-min melting step at 95ºC followed by 40 cycles at 95ºC for 10s 
and 60ºC for 60s. 
Relative mRNA levels of the genes of interest were normalized to -actin expression 
using the simplified comparative threshold cycle delta CT method [2 -(∆CT gene of interest-
∆CT β-actin].  
2.7. Confocal laser scanning microscopy 
Immortalized lymphocytes from control and PD individuals were seeded at an initial 
density of 1 x 106 cells x mL-1, synchronized in serum-free RPMI medium for 24 
hours, and incubated in the presence of serum for 24 hours. Cells were fixed for 15 
minutes in 4% paraformaldehyde, washed in PBS/BSA and cytospinned at 700 rpm 
for 7 minutes onto poly-L-lysine-coated slides. Then, they were blocked and 
permeabilized with 0.5% Triton X-100 in PBS-0.5% BSA for 20 minutes at room 
temperature and incubated with rabbit anti-TDP-43 antibody (Proteintech Group). 
After washing with PBS, cells were incubated with Alexa Fluor 488-conjugated anti-
rabbit antibody. The preparations were mounted on ProLong® Gold Antifade Reagent 
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with DAPI (Thermo Fisher) and visualized with the LEICA TCS-SP5-AOBS 
confocal microscope system (Heidelberg, Germany). 
2.8. Statistics 
Statistical analyses were performed on GraphPad Prism 5 for Macintosh (La Jolla, 
CA, USA). All the statistical data are presented as mean ± standard error of the mean 
(SEM). Statistical significance was estimated using an unpaired, two-tailed Student’s 




3. R ESU L TS 
 
3.1 Proliferative activity of lymphoblasts f rom control and PD patients. 
We generated lymphoblastoid cell lines by transforming lymphocytes, derived from 
control and sporadic PD patients, with the Epstein Barr virus, and compared the 
proliferative activity of these cell lines by direct cell counting over time. Fig. 1A 
shows a time-course analysis of the rate of proliferation of lymphoblasts from control 
and PD patients. For these experiments, cells were seeded at an initial density of 1 x 
106 cells x mL-1, synchronized by serum-starvation, grown in the presence of 10% 
FBS and counted for three days thereafter. PD cells exhibited increased proliferation 
rates compared with those of control cells (Fig. 1A). This observation was confirmed 
by assessing the rate of BrdU incorporation into DNA (Fig. 1B). 
3.2 Expression of key cell cycle regulatory proteins in control and PD 
lymphoblasts. 
Cell cycle disturbances in neurodegenerative disorders appear to involve a G1/S 
checkpoint failure [19]. The passage through this restriction point is regulated by 
several proteins, i.e, the pRb family of proteins, cyclins, cyclin-dependent kinases 
(CDKs) and CDK inhibitors. Therefore, we performed time-course analyses to assess 
possible differences in their expression levels in PD and control cells. 
First, we analyzed the levels and phosphorylation status of pRb and related proteins 
p130 and p107, that control the passage  through  the  restriction point  in  late G1 and 
commitment  to  DNA  synthesis  [20].  When hypophosphorylated, these proteins 
associate with E2F inhibiting cell cycle progression. The phosphorylation of these 
proteins causes their dissociation from E2F allowing the cells to enter S phase. Hypo­ 
and  hyperphosphorylated  forms  of  these  proteins  are  easily  distinguished  in  SDS­
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polyacrylamide gels. Both  forms were present at  zero  time  (Fig. 2). Serum addition 
induced the phosphorylation of pRb, p130, and p107, reaching maximum levels at 24­
48 hours as shown in the representative time­course experiments presented in Fig. 2 
(upper  panel).  Further  analyses  were  therefore  carried  out  after  24  hours  of  serum 
stimulation.  Levels  and  phosphorylation  of  these  pocket  proteins were  significantly 
increased  in  lymphoblasts  from PD patients  relative  to  those  found  in  control  cells 
after 24 hours of serum stimulation (Fig. 2, lower panel). Levels and phosphorylation 
of these pocket proteins were increased in lymphoblasts from PD patients relative to 
those found in control cells (Fig. 2). Since pRb and related proteins are sequentially 
phosphorylated by different cyclin/CDK complexes: cyclin D–CDK4/6 and cyclin E-
CDK2 [21,22], we analyzed the levels of those cyclins and CDKs after serum 
addition. As shown in Fig. 3, we didn’t observe any differences in the levels of cyclin 
D2 or cyclin E between control and PD patients. However, we found substantial 
higher levels of cyclin D3, 24 h after serum stimulation, in PD lymphoblasts when 
compared to control cells (Fig. 3, lower panel).  Cyclin D1  couldn’t  be  detected  in 
these cells. Moreover, we also observed increased CDK6 levels in PD cells, whereas 
CDK2 or CDK4 levels remained similar in control and PD patients (Fig. 4A). Fig. 4A 
(left panel) shows representative immunoblots of time course experiments, while Fig. 
4A (right panel) shows the quantified densitometric analyses of the corresponding 
proteins in cell extracts prepared from cells harvested 24 hours after serum 
stimulation. As the regulation of these cyclin-CDK complexes may be controlled by 
CDK inhibitors, we also analyzed the cellular content of different members of the 
Cip/Kip (p21, p27) and the INK4 (p16, p18) families of CDK inhibitors. Fig. 4B 
depicts no differences in p27, p16 and p18 content between control and PD patients, 
whereas p21 levels appear to be significantly lower in PD lymphoblasts than in 
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control cells (Fig. 4B, right panel).    
 
3.3 Regulation of the cellular content of C D K6, cyclin D3 and p21 in PD 
lymphoblasts. 
To evaluate the molecular mechanisms involved in the changes in the cellular content 
of CDK6, cyclin D3 and p21 of PD lymphoblasts, we considered whether the 
differences were due to an altered expression of the genes encoding those proteins or 
rather to a post-translational mechanism. Fig. 5 depicts the relative changes in mRNA 
and protein levels of CDK6, cyclin D3 and p21 following 24 hours of serum 
stimulation. It is shown that CDK6 mRNA levels were higher in lymphoblasts from 
PD patients than in control (Fig. 5A), in consonance with the protein levels observed 
(Fig. 5B), while mRNA levels of cyclin D3 and p21 were similar in control and PD 
(Fig. 5A), despite the differences found in the levels of these two proteins between 
control and PD cells (Fig. 5B). We then analyzed the half-life of those proteins to 
evaluate their stability. After 24 hours of serum addition, cells were treated with 
cycloheximide (CHX) to inhibit the de novo protein synthesis, and the cellular levels 
of the proteins were studied at different times thereafter. As shown in Fig. 6 (upper 
panel), CDK6 had a long half-life, similar in both control and PD lymphoblasts (26.1 
hours and 26.5 hours respectively). Conversely, cyclin D3 and p21 had a much 
shorter half-life. Inhibition of protein synthesis by cycloheximide led to a rapid 
degradation of cyclin D3, being the rate of degradation slower in PD patients (where 
the half-life was 65 minutes) than in control individuals (where the half-life was 40 
minutes) (Fig. 6, middle panel). On the other hand, degradation of p21 also appears to 
be altered in PD lymphoblasts, but in an opposite direction than cyclin D3. Half-life 
of the protein was 66 minutes in control cells, and 47 minutes in PD lymphoblasts, 
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indicating a more rapid degradation of the protein in the cells of the patients suffering 
from PD (Fig. 6, lower panel). Taken together, the data suggest that the increase in 
CDK6 protein levels may be explained by the higher expression of the corresponding 
gene, while differences in cyclin D3 and p21 levels seem to depend on changes in the 
rate of protein degradation. 
3.4 Subcellular distr ibution of T DP-43 and C D K6 expression. 
The following experiments were performed based on two pieces of information: first, 
it was reported that the expression of CDK6, but not of the others CDKs, is negatively 
regulated by the transactivation response DNA-binding protein 43 (TDP-43) [23], and 
second, it has been recently reported that TDP-43-positive inclusions occur in 
different neurodegenerative disorders including PD [24,25]. It is believed that TDP-
43 inclusions result from altered trafficking of TDP-43 from the nucleus to the 
cytoplasm. For these reasons, we considered the possibility that in PD cells, the 
accumulation of this protein in the cytosol could induce the loss of the nuclear 
function of TDP-43 repressing the expression of CDK6. To test this idea, we carried 
out fractionation of cell extracts from control and PD lymphoblasts to enrich for 
nuclear or cytoplasmic proteins and processed them for western-blot with an anti-
TDP-43 antibody. In addition, cells were analyzed by confocal laser imaging after 
immunostaining. Fig. 7A shows that cytosolic TDP-43 levels were significantly 
higher in PD cells compared to control lymphoblasts. Unexpectedly, we found that 
the nuclear levels of TDP-43 were not statistically different between control and PD 
cells (Fig. 7A). Similar results were observed with confocal laser imaging (Fig. 7C). 
An analogous finding was reported in a 3xTg mouse model of AD [26], suggesting 
that the increase of the levels in the cytosolic fraction is not simply due to a 
redistribution of TDP-43 from the nucleus into the cytoplasm. We studied the levels 
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of TDP-43 in the whole cell and observed that, in fact, total levels of the protein were 
increased in PD patients compared to control cells (Fig. 7B), suggesting that the 
increase in the cytosolic levels of the protein may be due to the general increase in the 
total content of the protein rather than to a redistribution of the protein from the 
nucleus. 
3.5 E ffects of sodium butyrate, PD-332991, and rapamycin on the proliferative 
activity of control and PD lymphoblasts. 
The above-presented results point at the increased expression and activity of the 
complex cyclin D3/CDK6 as the key factors involved in the overstimulation of PD 
cells proliferation. For this reason, we were interested in analyzing the role of this 
complex in PD lymphoblasts and used drugs specifically targeting CDK6: sodium 
butyrate (NaB), to inhibit the expression of the mRNA CDK6 [27], and a specific 
inhibitor of CDK6-associated kinase activity developed by Pfizer, PD-332991. On the 
other hand, we evaluated the effects of rapamycin on proliferation of control and PD 
lymphoblasts. This drug has been shown to down-regulate cyclin D3 levels by 
activating its degradation in the proteasome [28]. As shown in Fig. 8, treatment of PD 
lymphoblasts with NaB (10 M) or PD-332991 (1 µM) resulted in a significant 
inhibition of cell proliferation, assessed by direct cell counting (Fig. 8A) or by 
determining the incorporation of BrdU into DNA (not shown). These doses were 
selected based in previous work from our laboratory [29]. NaB and PD-332991 
changed little the proliferation of lymphoblasts from control individuals. The effects 
of these drugs on the cellular levels of CDK6, and phosphorylation status of pRb are 
shown in Fig. 8B. Treatment of PD cells with NaB decreased the content of the CDK6 
protein to levels similar to those of control cells. As expected, NaB was able to 
decrease the phosphorylation status of pRb in lymphoblasts from PD cells (Fig. 8B). 
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On the other hand, PD-332991, induced dephosphorylation of pRb protein without 
changes in the CDK6 protein levels in control and PD cells. 
The effect of decreasing the cellular cyclin D3 levels by rapamycin on cell 
proliferation is presented in Fig. 8C. This drug partially inhibited the enhanced 
proliferation of PD lymphoblasts, affecting very little the proliferative activity of 
control cells. Fig. 8D shows the effectiveness of rapamycin in decreasing cyclin D3 
levels and phosphorylation of pRb protein. 
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4. D ISC USSI O N 
 
In this work we provide evidence that immortalized lymphocytes from sporadic PD 
patients show alterations in cell cycle progression and significant changes in key 
regulatory molecules of the G1/S transition checkpoint. These observations are in line 
with previous reports from this and other laboratories indicating cell cycle 
deregulation in peripheral cells from patients suffering from neurodegenerative 
diseases as Alzheimer’s disease or frontotemporal dementia [30-33]. Moreover, these 
cell cycle disturbances were considered systemic manifestations of the disease, as 
aberrant activation of cell cycle is thought to be underlying neuronal apoptosis 
[34,35]. Neurons are postmitotic cells that have exited the cell cycle irreversibly and 
if they are forced to enter the cell cycle, they die.  
The increased proliferation of lymphoblasts from PD patients is accompanied by 
enhanced phosphorylation of pRb protein, thereby allowing the transcription of genes 
that promote the mechanics of the cell cycle [36]. The higher phosphorylation of pRb 
observed in PD cells is, most likely, due to the increased levels of the two components 
of the cyclin D3/CDK6 complex. Despite the fact that pRb is sequentially 
phosphorylated by 2 sets of protein kinases, the cyclin D/CDK4/CDK6 and cyclin 
E/CDK2, we did not observe differences in expression levels of other cyclins or 
CDKs between control and PD lymphoblasts. In addition, we found a decrease in the 
levels of the CDK inhibitor p21, which can also contribute to the increased 
phosphorylation of pRb. 
The results presented herein indicate that altered levels of cyclin D3 and p21 observed 
in PD cells are due to altered degradation of these proteins. A longer half-life of 
cyclin D3 protein was detected in PD lymphoblasts as compared with controls cells, 
while p21 seems to be degraded more rapidly in PD cells. Changes in the rate of 
 18 
degradation of cyclin D3 and p21 are not due to nonspecific impairment of general 
protein degradation in lymphoblasts from PD cells, as half-life of CDK6 is not 
altered.  These results are in agreement with previous work indicating that both p21 
and cyclin D3 content are translationally regulated in a number of cell types [37,38]. 
The PI3K/Akt/mTOR pathway seems to be involved in cyclin D3 degradation and 
enhanced cell proliferation [28,39]. Thus, the possibility should be considered that 
this survival pathway is overactivated in PD cells. 
Upregulation of CDK6 in PD cells appears to occur at the transcriptional level. 
Quantitative RT-PCR analyses demonstrated higher levels of CDK6 mRNA in 
lymphoblasts derived from PD patients when compared with those in control cells. 
The transcriptional regulation of CDK6 is achieved through distinct mechanisms. We 
investigated a possible relation between CDK6 expression and nuclear levels of TDP-
43 protein. TDP-43 represses CDK6 expression by binding to GT repeats that are 
present, once or twice, in the long exons of CDK6, but not in other human CDK6 
genes [23]. On these grounds, we considered the possibility of a loss of function of 
TDP-43 secondary to changes in the nuclear content of this protein in PD cells as it 
has been described to occur in frontotemporal lobar degeneration [40,41]. Significant 
changes in both total and cytosolic levels of TDP-43 were found in PD lymphoblasts, 
however, we couldn’t detect diminished levels of nuclear TDP-43 to account for the 
higher CDK6 mRNA levels of PD cells. Nonetheless it is worth to mention that other 
authors reported increased expression of CDK6 by TDP-43 in CHO-K1 cells, 
apparently stabilizing its mRNA rather than inhibiting pre-mRNA splicing [42].  It 
remains to be resolved whether or not the TDP-43-mediated control of CDK6 
expression is cell specific, and the role of TDP-43, if any, in the upregulation of 
CDK6 and enhanced proliferation found in PD cells. 
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On the other hand, CDK6 content appears to be negatively regulated by several 
miRNAs including miR-29 [43], miR-16 [44], miR-22 [45] and miR-34b [46], the 
levels of which have been shown to be downregulated in PD patients [47-49]. Thus, it 
is possible that CDK6 abundance in peripheral cells from PD patients may depend on 
both transcriptional and post-transcriptional events. Further work will be needed to 
clarify this point. 
 
In summary, our results established a molecular link between increased CDK6 and 
cyclin D3 levels, pRb phosphorylation, and proliferation of lymphoblasts from 
sporadic PD patients. Activation of the pRb pathway has been reported in PD brain 
and in mouse models of PD [7], although in neurons this leads to cell death rather 
than to cell division. Thus, our results support the hypothesis that unscheduled cell 
cycle activation underlies neurodegeneration, and highlight the usefulness of 
peripheral cells from PD patients as potential surrogate for diagnosis and therapeutic 
monitoring of PD. It is suggested that therapeutic interventions aimed at ameliorating 
cell cycle progression activity may have a positive impact in PD. On these grounds, it 
is worth mentioning that rapamycin, NaB, and PD-332991 are able to restore the 
normal cell response by decreasing the levels of cyclin D3, CDK6 expression, or the 
associated kinase activity.  
NaB and rapamycin have been shown to have neuroprotective properties in various 
PD-related experimental models in vitro and in vivo [50-53]. Rapamycin and CDK6 
inhibitors are already being used as immunosuppressant and for treatment of a 
number of human tumors, respectively [54,55], with a good tolerance. Therefore, we 
believe that the cyclin D3/CDK6 complex could be considered as a novel therapeutic 
target for PD, and that the repositioning of these drugs towards PD treatment, may 
offer a significant advantage over traditional drug development.   
 20 
A C K N O W L E D G E M E N TS 
 
This work has been supported by grants from Ministerio de Economía y 
Competitividad (SAF2011-28603) and Fundación Ramón Areces to AMR, and 
Fundación Neurociencias y Envejecimiento to JAM. We would like to thank to all 
patients, their families and clinicians involved in this study. The skillful technical 
assistance of Eduardo Parrilla is greatly appreciated. 
 21 
R E F E R E N C ES  
1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, 
Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence 
of Parkinson's disease in Europe: A collaborative study of population-based cohorts. 
Neurologic Diseases in the Elderly Research Group. Neurology 54 (11 Suppl 5):S21-
23 
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) 
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 
24 (2):197-211 
3. Mallucci G (2013) Spreading proteins in neurodegeneration: where do they take 
us? Brain 136 (Pt 4):994-995. doi:10.1093/brain/awt072 
4. Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson's--divergent causes, 
convergent mechanisms. Science 304 (5674):1120-1122. 
doi:10.1126/science.1098966 
5. Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, Memo M (2001) 
Activation of cell-cycle-associated proteins in neuronal death: a mandatory or 
dispensable path? Trends Neurosci 24 (1):25-31 
6. Herrup K, Neve R, Ackerman SL, Copani A (2004) Divide and die: cell cycle 
events as triggers of nerve cell death. J Neurosci 24 (42):9232-9239. 
doi:10.1523/jneurosci.3347-04.2004 
7. Hoglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, 
Boutillier AL, Degregori J, Oertel WH, Rakic P, Hirsch EC, Hunot S (2007) The 
pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl 
Acad Sci U S A 104 (9):3585-3590. doi:10.1073/pnas.0611671104 
8. Mandel SA, Fishman T, Youdim MB (2007) Gene and protein signatures in 
sporadic Parkinson's disease and a novel genetic model of PD. Parkinsonism Relat 
Disord 13 Suppl 3:S242-247. doi:10.1016/s1353-8020(08)70009-9 
9. Mutez E, Larvor L, Lepretre F, Mouroux V, Hamalek D, Kerckaert JP, Perez-Tur J, 
Waucquier N, Vanbesien-Mailliot C, Duflot A, Devos D, Defebvre L, Kreisler A, 
Frigard B, Destee A, Chartier-Harlin MC (2011) Transcriptional profile of Parkinson 
blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 32 (10):1839-1848. 
doi:10.1016/j.neurobiolaging.2009.10.016 
10. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild 
MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, 
Growdon JH, Jensen RV, Gullans SR (2007) Molecular markers of early Parkinson's 
disease based on gene expression in blood. Proc Natl Acad Sci U S A 104 (3):955-
960. doi:10.1073/pnas.0610204104 
11. Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene 
expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B 
(3):261-268. doi:10.1002/ajmg.b.30272 
12. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, 
Tayebati SK (2001) Identification of dopamine plasma membrane and vesicular 
transporters in human peripheral blood lymphocytes. J Neuroimmunol 117 (1-2):133-
142 
 22 
13. Shinde S, Pasupathy K (2006) Respiratory-chain enzyme activities in isolated 
mitochondria of lymphocytes from patients with Parkinson's disease: preliminary 
study. Neurol India 54 (4):390-393 
14. Blandini F, Sinforiani E, Pacchetti C, Samuele A, Bazzini E, Zangaglia R, Nappi 
G, Martignoni E (2006) Peripheral proteasome and caspase activity in Parkinson 
disease and Alzheimer disease. Neurology 66 (4):529-534. 
doi:10.1212/01.wnl.0000198511.09968.b3 
15. Bartolome F, de Las Cuevas N, Munoz U, Bermejo F, Martin-Requero A (2007) 
Impaired apoptosis in lymphoblasts from Alzheimer's disease patients: cross-talk of 
Ca2+/calmodulin and ERK1/2 signaling pathways. Cell Mol Life Sci 64 (11):1437-
1448. doi:10.1007/s00018-007-7081-3 
16. Munoz U, Bartolome F, Bermejo F, Martin-Requero A (2008) Enhanced 
proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized 
lymphocytes from Alzheimer's dementia patients. Neurobiol Aging 29 (10):1474-
1484. doi:10.1016/j.neurobiolaging.2007.03.013 
17. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. 
Arch Neurol 56 (1):33-39 
18. Ibarreta D, Urcelay E, Parrilla R, Ayuso MS (1998) Distinct pH homeostatic 
features in lymphoblasts from Alzheimer's disease patients. Ann Neurol 44 (2):216-
222. doi:10.1002/ana.410440212 
19. Nagy Z (2007) The dysregulation of the cell cycle and the diagnosis of 
Alzheimer's disease. Biochim Biophys Acta 1772 (4):402-408. 
doi:10.1016/j.bbadis.2006.11.001 
20. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81 
(3):323-330 
21. Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma 
protein requires sequential modification by at least two distinct cyclin-cdk complexes. 
Mol Cell Biol 18 (2):753-761 
22. Mittnacht S (1998) Control of pRB phosphorylation. Curr Opin Genet Dev 8 
(1):21-27 
23. Ayala YM, Misteli T, Baralle FE (2008) TDP-43 regulates retinoblastoma protein 
phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc 
Natl Acad Sci U S A 105 (10):3785-3789. doi:10.1073/pnas.0800546105 
24. Chanson JB, Echaniz-Laguna A, Vogel T, Mohr M, Benoilid A, Kaltenbach G, 
Kiesmann M (2010) TDP43-positive intraneuronal inclusions in a patient with motor 
neuron disease and Parkinson's disease. Neurodegener Dis 7 (4):260-264. 
doi:10.1159/000273591 
25. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, 
Katsuse O, Uchikado H, Furukawa Y, Kosaka K, Arai H (2007) Concurrence of TDP-
43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia 
with Lewy bodies. Brain Res 1184:284-294. doi:10.1016/j.brainres.2007.09.048 
26. Caccamo A, Magri A, Oddo S (2010) Age-dependent changes in TDP-43 levels in 
a mouse model of Alzheimer disease are linked to Abeta oligomers accumulation. 
Mol Neurodegener 5:51. doi:10.1186/1750-1326-5-51 
 23 
27. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone 
deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat 
permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol 
Exp Ther 321 (3):892-901. doi:10.1124/jpet.107.120188 
28. Garcia-Morales P, Hernando E, Carrasco-Garcia E, Menendez-Gutierrez MP, 
Saceda M, Martinez-Lacaci I (2006) Cyclin D3 is down-regulated by rapamycin in 
HER-2-overexpressing breast cancer cells. Mol Cancer Ther 5 (9):2172-2181. 
doi:10.1158/1535-7163.mct-05-0363 
29. Alquezar C, Esteras N, Alzualde A, Moreno F, Ayuso MS, Lopez de Munain A, 
Martin-Requero A (2012) Inactivation of CDK/pRb pathway normalizes survival 
pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A. 
PLoS One 7 (5):e37057. doi:10.1371/journal.pone.0037057 
30. Alquezar C, Esteras N, Bartolome F, Merino JJ, Alzualde A, Lopez de Munain A, 
Martin-Requero A (2012) Alteration in cell cycle-related proteins in lymphoblasts 
from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP 
dementia. Neurobiol Aging 33 (2):429 e427-420. 
doi:10.1016/j.neurobiolaging.2010.11.020 
31. Bialopiotrowicz E, Kuzniewska B, Kachamakova-Trojanowska N, Barcikowska 
M, Kuznicki J, Wojda U (2011) Cell cycle regulation distinguishes lymphocytes from 
sporadic and familial Alzheimer's disease patients. Neurobiol Aging 32 (12):2319 
e2313-2326. doi:10.1016/j.neurobiolaging.2010.04.017 
32. de las Cuevas N, Urcelay E, Hermida OG, Saiz-Diaz RA, Bermejo F, Ayuso MS, 
Martin-Requero A (2003) Ca2+/calmodulin-dependent modulation of cell cycle 
elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts 
from patients with Alzheimer dementia. Neurobiol Dis 13 (3):254-263 
33. Nagy Z, Combrinck M, Budge M, McShane R (2002) Cell cycle kinesis in 
lymphocytes in the diagnosis of Alzheimer's disease. Neurosci Lett 317 (2):81-84 
34. Hernandez-Ortega K, Quiroz-Baez R, Arias C (2011) Cell cycle reactivation in 
mature neurons: a link with brain plasticity, neuronal injury and neurodegenerative 
diseases? Neurosci Bull 27 (3):185-196. doi:10.1007/s12264-011-1002-z 
35. Husseman JW, Nochlin D, Vincent I (2000) Mitotic activation: a convergent 
mechanism for a cohort of neurodegenerative diseases. Neurobiol Aging 21 (6):815-
828 
36. Polager S, Ginsberg D (2008) E2F - at the crossroads of life and death. Trends 
Cell Biol 18 (11):528-535. doi:10.1016/j.tcb.2008.08.003 
37. Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, Zuckerman 
KS (2002) Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to 
tumor necrosis factor-induced cell cycle arrest. J Biol Chem 277 (19):16528-16537. 
doi:10.1074/jbc.M109929200 
38. Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and 
cancer. Nat Rev Cancer 6 (5):369-381. doi:10.1038/nrc1881 
39. Hleb M, Murphy S, Wagner EF, Hanna NN, Sharma N, Park J, Li XC, Strom TB, 
Padbury JF, Tseng YT, Sharma S (2004) Evidence for cyclin D3 as a novel target of 
rapamycin in human T lymphocytes. J Biol Chem 279 (30):31948-31955. 
doi:10.1074/jbc.M400638200 
 24 
40. Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M, 
Kremmer E, Matsuwaki T, Yamanouchi K, Nishihara M, Haass C (2009) Proteolytic 
processing of TAR DNA binding protein-43 by caspases produces C-terminal 
fragments with disease defining properties independent of progranulin. J Neurochem 
110 (3):1082-1094. doi:10.1111/j.1471-4159.2009.06211.x 
41. Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, 
Dickson D, Petrucelli L (2007) Progranulin mediates caspase-dependent cleavage of 
TAR DNA binding protein-43. J Neurosci 27 (39):10530-10534. 
doi:10.1523/jneurosci.3421-07.2007 
42. Liu X, Li D, Zhang W, Guo M, Zhan Q (2012) Long non-coding RNA gadd7 
interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J 31 (23):4415-
4427. doi:10.1038/emboj.2012.292 
43. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, 
Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ (2010) microRNA expression 
profile and identification of miR-29 as a prognostic marker and pathogenetic factor by 
targeting CDK6 in mantle cell lymphoma. Blood 115 (13):2630-2639. 
doi:10.1182/blood-2009-09-243147 
44. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008) miR-
16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic 
Acids Res 36 (16):5391-5404. doi:10.1093/nar/gkn522 
45. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, 
Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H (2011) miR-22 represses 
cancer progression by inducing cellular senescence. J Cell Biol 193 (2):409-424. 
doi:10.1083/jcb.201010100 
46. Smorag L, Zheng Y, Nolte J, Zechner U, Engel W, Pantakani DV (2012) 
MicroRNA signature in various cell types of mouse spermatogenesis: evidence for 
stage-specifically expressed miRNA-221, -203 and -34b-5p mediated 
spermatogenesis regulation. Biol Cell 104 (11):677-692. doi:10.1111/boc.201200014 
47. Margis R, Rieder CR (2011) Identification of blood microRNAs associated to 
Parkinsonis disease. J Biotechnol 152 (3):96-101. doi:10.1016/j.jbiotec.2011.01.023 
48. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, 
Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E (2011) MicroRNA profiling of 
Parkinson's disease brains identifies early downregulation of miR-34b/c which 
modulate mitochondrial function. Hum Mol Genet 20 (15):3067-3078. 
doi:10.1093/hmg/ddr210 
49. Soreq L, Salomonis N, Bronstein M, Greenberg DS, Israel Z, Bergman H, Soreq 
H (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal 
deep brain stimulation-induced splicing changes that classify brain region 
transcriptomes. Front Mol Neurosci 6:10. doi:10.3389/fnmol.2013.00010 
50. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M 
(2010) Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 30 
(37):12535-12544. doi:10.1523/jneurosci.1920-10.2010 
51. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) 
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's 
disease. J Neurosci 30 (3):1166-1175. doi:10.1523/jneurosci.3944-09.2010 
 25 
52. Rane P, Shields J, Heffernan M, Guo Y, Akbarian S, King JA (2012) The histone 
deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage 
PD. Neuropharmacology 62 (7):2409-2412. doi:10.1016/j.neuropharm.2012.01.026 
53. St Laurent R, O'Brien LM, Ahmad ST (2013) Sodium butyrate improves 
locomotor impairment and early mortality in a rotenone-induced Drosophila model of 
Parkinson's disease. Neuroscience 246:382-390. 
doi:10.1016/j.neuroscience.2013.04.037 
54. Bove J, Martinez-Vicente M, Vila M (2011) Fighting neurodegeneration with 
rapamycin: mechanistic insights. Nat Rev Neurosci 12 (8):437-452. 
doi:10.1038/nrn3068 
55. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C (2007) HDACs, 
histone deacetylation and gene transcription: from molecular biology to cancer 
therapeutics. Cell Res 17 (3):195-211. doi:10.1038/sj.cr.7310149 
  
 26 
F I G UR E L E G E NDS 
 
F igure 1 
Proliferation of lymphoblasts f rom control and PD patients 
A . Control and PD lymphoblasts were seeded at an initial density of 1 x 106 cells x 
mL-1 and synchronized by serum starvation for 24 hours. On that point, 10% FBS was 
added and cells were incubated for 72 hours. Samples were taken every 24 hours after 
serum addition and counted in a Neubauer chamber. Values shown represent mean ± 
SEM of different experiments carried out with 20 control and 20 PD patients. Every 
individual was counted at least twice.  B . After synchronization by serum starvation 
for 24 hours, 100,000 cells/well were seeded in 96-well plates in the presence of 10% 
FBS. After 24 hours, 10 µM BrdU was added to the medium for 4 hours. BrdU 
incorporation into DNA was detected according to manufacturer instructions. The 
magnitude of the absorbance is proportional to the quantity of BrdU incorporated into 
cells, which is a direct indicator of cell proliferation. Data represent the mean ± SEM 
of different experiments carried out with 4 control and 4 PD patients. *p<0.05, 
significantly different from control cells. 
F igure 2 
Retinoblastoma protein (pRb) family levels and phosphorylation status 
Lymphoblasts from control and PD patients were seeded at an initial density of 1 x 
106 cells x mL-1 and synchronized by serum starvation for 24 hours. 10% FBS was 
added and cells were incubated for 72 hours. Four million cells were taken every 24 
hours after serum addition and whole-cell lysates were prepared to perform Western 
Blot analyses. pRb-family protein levels were detected using phospho-specific anti-
pRb, anti-p130 and anti-p107 antibodies.  Representative immunoblots for time-
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course experiments are shown. In the lower panel it is shown the mean±SEM of the 
quantification of the band densities 24 hours after serum addition, when the proteins 
reach the maximum levels. A total of 5 control and 5-7 PD patients were analyzed. 
*p<0.05, significantly different from control. A representative experiment is shown. 
pp = the hyperphosphorylated form of the corresponding protein. 
F igure 3 
T ime course analysis of the cyclins involved in G1-S in control and PD patients 
Immortalized lymphocytes from control and PD patients were seeded at an initial 
density of 1 x 106 cells x mL-1, synchronized by serum-starvation and incubated for 
72 hours in the presence of 10% FBS. Whole-cell lysates where prepared every 24 
hours after serum addition to analyze cyclin D2, cyclin D3 and cyclin E levels by 
Western Blot.  Representative immunoblots for time-course experiments are shown. 
Values shown in the lower panel represent the mean±SEM of the quantification of the 
band densities 24 hours after serum addition. A total of 8-14 control and 8-16 PD 
patients were used in the experiments. *p<0.05, significantly different from control.  
F igure 4 
T ime course analysis of the C D Ks and C D K inhibitors involved in G1-S in 
control and PD patients 
Lymphoblasts from control and PD patients were seeded at an initial density of 1 x 
106 cells x mL-1 and synchronized by serum starvation for 24 hours. 10% FBS was 
added and cells were incubated for 72 hours. Whole-cell lysates were prepared every 
24 hours after serum addition to analyze CDK family (CDK2, CDK4 and CDK6) 
levels, as well as Cip/Kip (p21, p27) and INK4 (p16, p18) families of CDK inhibitors 
levels by Western Blot. A , B (left panels). Representative immunoblots for time-
course experiments are shown. A , B (right panels). Values shown represent the 
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mean±SEM of the quantification of the band densities 24 hours after serum addition. 
8-14 control and 8-16 PD patients were analyzed. **p<0.01, significantly different 
from control.  
 
F igure 5 
Protein and mRN A levels of C D K6, cyclin D3 and p21 in control and PD 
lymphoblasts 
Lymphoblasts from control and PD patients were seeded at an initial density of 1 x 
106 cells x mL-1 and synchronized by serum starvation for 24 hours. 10% FBS was 
added and cells were incubated for 24 hours to perform the following experiments: A . 
RNA was extracted, reverse-transcribed and subjected to qRT-PCR to analyze the 
differences in mRNA content. β-actin was used as housekeeping gene. Values shown 
represent the mean ± SEM of different experiments carried out with 8-9 control and 
8-10 PD patients. *p<0.05, significantly different from control cells. B . Whole-cell 
extracts were prepared to analyze by Western-Blot the levels of CDK6, cyclin D3 and 
p21. A representative experiment is shown. Data represent mean ± SEM of different 
experiments carried out with 14 control and 16 PD patients. β-actin was used as 
loading control. *p<0.05, significantly different from control, **p<0.01, significantly 
different from control.  
F igure 6 
Degradation rate of C D K6, cyclin D3 and p21 in control and PD lymphoblasts 
Experiments were performed in the same conditions as Figure 5. 24 hours after serum 
addition, cycloheximide (CHX) (20 g/mL) was added to the medium and cells were 
harvested at 0, 6, 12, 24 and 36 hours thereafter for CDK6 experiments; or 0, 0.5, 1, 
1.5, 2, 3 hours thereafter for cyclin D3 and p21 experiments. Whole-cell extracts were 
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prepared at those times to analyze the protein content by Western-blot. A 
representative experiment is shown. The graph shows the decay of the protein signal, 
taking the levels of the protein of either control or PD lymphoblasts at time = 0 hours 
as 100%. Results represent the mean ± SEM of different experiments carried out with 
4 control and 4 PD patients 
F igure 7 
Subcellular localization and content of T DP-43 in control and PD lymphoblasts 
Control and PD lymphoblasts were seeded at an initial density of 1 x 106 cells x mL-1 
and serum-starved for 24 hours. After that, 10% FBS was added and cells were 
incubated for 24 hours. Lymphoblasts were then collected for the different 
experiments: A . Cells were lysed as described in Methods to separate nuclear and 
cytosolic  fragments  and  then  analyzed  by  Western  Blot.  Lamin  B  and  α-tubulin 
antibodies were used as loading and purity control of the nuclear and cytosolic 
fractions, respectively. A representative experiment is shown. Data represent mean ± 
SEM of different experiments using 11 control and 11 PD patients. **p<0.01 
significantly different from control cytosol. B . Whole-cell extracts were prepared to 
analyze the total content of TDP-43 of the cells by Western Blot. A representative 
experiment is shown. Data represent mean ± SEM of different experiments carried out 
with 12 control and 12 PD patients. β-actin was used as loading control. **p<0.01 
significantly different from control. C . Subcellular localization of TPD-43 was also 
studied by confocal microscopy. Cells were stained with anti-TDP-43 antibody 
followed by secondary antibody labeling with Alexa Fluor 488. DAPI was included in 
the mounting media to stain the nucleus. Merged images show a predominant nuclear 
localization of TPD-43, being cytosolic localization higher in PD patients than in 
control cells. Magnification: 63X.  
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F igure 8 
E ffects of NaB , PD-332991, and rapamycin on the proliferative activity of control 
and PD lymphoblasts 
For all the experiments, control and PD lymphoblasts were seeded at an initial density 
of 1 x 106 cells x mL-1 and synchronized by serum starvation for 24 hours. On that 
point, 1 M PD-332991, 10 M NaB, or 30 ng/mL rapamycin plus 10% FBS were 
added. A . Cells were incubated for 72 hours. Samples were taken every 24 hours after 
serum and drugs addition and counted using an Automated Cell Counter from Bio-
Rad. Graph represents the number of cells in the different conditions after 72 hours of 
serum addition. Values shown represent mean ± SEM of different experiments carried 
out with 8 control and 8 PD patients. ** p<0.01 different from control cells, +p<0.05 
different from untreated PD cells, ++ p<0.01 different from untreated PD cells. Every 
individual was counted at least twice.  B . After 24 hours of serum and drugs addition, 
whole-cell extracts were prepared to analyze by Western Blot the cellular content of 
CDK6 and the phosphorylation status of pRb protein. A representative experiment is 
shown. C . Experimental conditions were identical to those described in A. Rapamycin 
was added at the concentration of 30 ng/mL. Data represent the mean ± SEM of 
different experiments carried out with 4 control and 4 PD patients. **p<0.01, 
significantly different from control cells, ++p<0.01 different from untreated PD cells. 
D. A representative experiment showing the effects of rapamycin on cyclin D3 levels 
and phosphorylation of pRb.  
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